Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of Mimrylo for Erythrocytosis in Polycythemia Vera Transcript

Impact · against what's priced in

Protagonist Therapeutics (PTGX) has achieved a major value-inflection point with the FDA approval of Mimrylo for erythrocytosis in Polycythemia Vera. This shifts the company from a clinical-stage entity to a commercial-stage one, creating a clear path to revenue generation.

PTGX+0.90

No priced-in read yet